Hologic (HOLX) Rating Reiterated by Canaccord Genuity

Share on StockTwits

Canaccord Genuity reissued their hold rating on shares of Hologic (NASDAQ:HOLX) in a research report sent to investors on Monday. They currently have a $41.00 price target on the medical equipment provider’s stock.

Several other analysts have also issued reports on the stock. Cowen lowered shares of Hologic from an outperform rating to a market perform rating and set a $38.28 target price for the company. in a research report on Friday, January 4th. Morgan Stanley lowered shares of Hologic from an equal weight rating to an underweight rating and dropped their price target for the stock from $44.00 to $39.00 in a research report on Wednesday, January 2nd. Royal Bank of Canada upped their price target on shares of Hologic from $40.00 to $46.00 and gave the stock a sector perform rating in a research report on Friday, November 30th. They noted that the move was a valuation call. BidaskClub upgraded shares of Hologic from a buy rating to a strong-buy rating in a research report on Wednesday, November 21st. Finally, Zacks Investment Research upgraded shares of Hologic from a sell rating to a hold rating in a research report on Tuesday, November 13th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Hologic currently has an average rating of Hold and a consensus price target of $43.33.

Shares of NASDAQ HOLX opened at $42.56 on Monday. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.95. The company has a market cap of $11.32 billion, a P/E ratio of 19.09, a price-to-earnings-growth ratio of 1.81 and a beta of 0.73. Hologic has a 12-month low of $35.10 and a 12-month high of $45.17.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, November 7th. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.59 by ($0.01). The business had revenue of $813.50 million for the quarter, compared to the consensus estimate of $808.63 million. Hologic had a negative net margin of 3.46% and a positive return on equity of 23.52%. The business’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.50 earnings per share. Equities research analysts anticipate that Hologic will post 2.4 EPS for the current year.

In other news, Director Christiana Stamoulis sold 13,257 shares of the business’s stock in a transaction on Wednesday, November 28th. The shares were sold at an average price of $44.50, for a total value of $589,936.50. Following the transaction, the director now owns 48,296 shares of the company’s stock, valued at $2,149,172. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Karleen Marie Oberton sold 1,312 shares of the business’s stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $41.90, for a total transaction of $54,972.80. Following the completion of the transaction, the chief financial officer now directly owns 10,206 shares in the company, valued at approximately $427,631.40. The disclosure for this sale can be found here. Insiders sold 36,355 shares of company stock worth $1,584,655 in the last three months. Insiders own 0.88% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. First Hawaiian Bank purchased a new stake in Hologic during the third quarter valued at $397,000. Nisa Investment Advisors LLC raised its stake in Hologic by 25.5% during the third quarter. Nisa Investment Advisors LLC now owns 68,426 shares of the medical equipment provider’s stock valued at $2,804,000 after purchasing an additional 13,906 shares in the last quarter. Bank of Montreal Can raised its stake in Hologic by 37.0% during the third quarter. Bank of Montreal Can now owns 370,187 shares of the medical equipment provider’s stock valued at $15,169,000 after purchasing an additional 99,888 shares in the last quarter. Aperio Group LLC raised its stake in Hologic by 8.0% during the third quarter. Aperio Group LLC now owns 87,436 shares of the medical equipment provider’s stock valued at $3,583,000 after purchasing an additional 6,493 shares in the last quarter. Finally, Capital Fund Management S.A. purchased a new stake in Hologic during the second quarter valued at $2,905,000. 91.77% of the stock is currently owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Read More: How do taxes affect a CDs total return?

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

UBS Group Reaffirms Buy Rating for Puma AG Rudolf Dassler Sport
UBS Group Reaffirms Buy Rating for Puma AG Rudolf Dassler Sport
Trevali Mining  Price Target Lowered to C$0.60 at National Bank Financial
Trevali Mining Price Target Lowered to C$0.60 at National Bank Financial
Robinson  Earns “Corporate” Rating from FinnCap
Robinson Earns “Corporate” Rating from FinnCap
Hastings Group  Earns “Overweight” Rating from Barclays
Hastings Group Earns “Overweight” Rating from Barclays
Deckers Outdoor  Scheduled to Post Earnings on Thursday
Deckers Outdoor Scheduled to Post Earnings on Thursday
Modine Manufacturing  to Release Earnings on Thursday
Modine Manufacturing to Release Earnings on Thursday


Leave a Reply

 
© 2006-2019 Zolmax.